Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Latuda® (lurasidone) – Expanded indication
January 28, 2017 – Sunovion announced the FDA approval of Latuda (lurasidone) for the treatment of adolescent patients aged 13 to 17 years with schizophrenia.
